¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acquired coagulation factor deficiency"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ
  • competence factor
    1. ¸é¿ª°¡´ÉÀÎÀÚ 2. ¹ÝÀÀ°¡´ÉÀÎÀÚ
  • competence inducing factor
    ¸é¿ª°¡´ÉÀ¯¹ßÀÎÀÚ
  • complementary factor
    º¸ÃæÀÎÀÚ
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • conversion factor
    º¯È¯ÀÎÀÚ, º¯È¯°è¼ö
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
  • corticotropin-releasing factor
    ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó¹æÃâÀÎÀÚ
  • chemotactic factor
    È­Çнò¸²ÀÎÀÚ
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • nutritional deficiency state
    ¿µ¾ç°áÇÌ»óÅÂ
  • nutritional deficiency syndrome
    ¿µ¾ç°áÇÌÁõÈıº
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • antihemophlic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÛ¿ëÀÎÀÚ
  • antirachitic factor
    Ç×±¸·íº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ
  • colonizing factor antigen
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
  • aspartylglycosamine amide hydrolase, deficiency
    Aspartylglycosamine amide hydrolase°áÇÌ(¡­ÌÀù¹)
  • functional deficiency
    ±â´É°áÇÌ
  • g6pd deficiency
    G6PD(Æ÷µµ´ç-6-Àλ꿰 Å»¼ö¼ÒÈ¿¼Ò) °áÇÌÁõ
  • galactosidase, alpha-galactosidase a, deficiency
    #NAME?
  • glucocerebrosidase deficiency
    ±Û·çÄÚ¼¼·¹ºê·Î½Ãµ¥À̽º °áÇÌÁõ
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glucuronidase deficiency disease
    ±Û·çÅ¥·Î´Ïµ¥À̽º °áÇÌÁõ
  • glutathione reductase deficiency
    ±Û·çŸƼ¿Â ȯ¿øÈ¿¼Ò °áÇÌÁõ.
  • glycosidase deficiency
    ±Û¸®ÄڽôپÆÁ¦°áÇÌ(Áõ).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
  • hepatophosphorylase deficiency
    °£Æ÷½ºÆ÷¸±¶ó¾ÆÁ¦°áÇÌÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • blood coagulation test
    Ç÷¾×ÀÀ°í½ÃÇè (¡­ãËúÐ).
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í(ëêͳ)
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀÌ»ó(¡­ì¶ßÈ), ÀÀ°íÀå¾Ö(¡­î¡äô).
  • coagulation disorder
    ÀÀ°íÀÌ»ó
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • coagulation necrosis
    ÀÀ°í±«»ç(¡­ÎÕÞÝ)
  • coagulation test
    ÀÀ°í½ÃÇè(ëêͳãËúÐ).
  • coagulation time
    ÀÀ°í½Ã°£(¡­ãÁÊà) ¡ìÇ÷¾×ÀÇ¡í.
  • coagulation,disseminated intravascular
    ÆÄÁ¾¼º Ç÷°ü³» ÀÀ°í(÷ëðúàõúìηҮ¡­)
  • coagulation,fibrinolytic system
    ¼¶À¯¼Ò ¿ëÇØ°è(àéë«áÈéÁú°Í§)
  • coagulation,intrinsic pathway
    ³»ºÎ °æ·Î(ҮݻÌèÖØ)
  • diffuse intravascular coagulation
    ¹ü¹ß¼º Ç÷°ü³»ÀÀ°í.
  • disseminated intravascular coagulation
    ÆÄÁ¾¼º Ç÷°ü³»ÀÀ°í(÷ëðúàõúìηҮëêͳ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • contact factor
    "Á¢ÃËÀÎÀÚ(ïÈõºì×í­), (ÔÒ) Hageman factor"
  • conversion factor
    ÀüȯÀÎÀÚ(ï®üµì×í­)
  • cord factor
    ÄÚµå ÀÎÀÚ(ì×í­)
  • coupling factor
    ¦Áþ±â ÀÎÀÚ(ì×í­)
  • decay factor
    "ºØ±« ÀÎÀÚ(ÝÚÎÕì×í­), (ÔÒ) decay constant"
  • diffusing factor
    "È®»êÀÎÀÚ(üªß¤ì×í­), (ÔÒ) hyaluronidase"
  • dissociation factor
    ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
  • egg white injury factor
    ÈØÀÚ ¼Õ»óÀÎÀÚ (áßß¿ì×í­)
  • elongation factor
    ¿¬ÀåÀÎÀÚ (æÅíþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
  • erythrocyte maturation factor
    ÀûÇ÷±¸ ¼º¼÷ ÀÎÀÚ (îåúìϹà÷âÙì×í­)
  • extrinsic factor
    ¿ÜÀÎÀÚ(èâì×í­)
  • factor
    ÀÎÀÚ(ì×í­)
  • factor ¥°
    ÀÎÀÚ(ì×í­) I
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
F2R [blood coagulation] factor II receptor
IGD idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency
MCD magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ...
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
AIDS HIV)-acquired immunodeficiency syndrome
HAI Hospital Acquired Infections
HAP Hospital-acquired pneumonia
HIV/AIDS Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
AIDS Non-acquired immunodeficiency syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immune deficiency disease
    ¸é¿ª °áÇÌ Áúȯ, ¸é¿ª °áÇ̺´
    ¸é¿ª °èÅëÀ» ±¸¼ºÇÏ´Â ¿ä¼ÒÀÇ ±â´É Àå¾Ö¿¡ ÀÇÇÏ¿© ÃÊ·¡µÇ´Â Áúȯ ±º.
  • immunity deficiency
    ¸é¿ª °áÇÌ
    µ¿ÀǾî=immunodeficiency.
  • immunological deficiency state
    ¸é¿ª °áÇÌ »óÅÂ
  • iron deficiency anemia
    ö °áÇ̼º ºóÇ÷
    1. Àú»ö¼Ò¼º, ¼Ò±¸¼º ÀûÇ÷±¸¼º ºóÇ÷ÀÇ ´ëÇ¥Àû Áúȯ. öÀÇ °áÇÌ¿¡ ÀÇÇÏ¿© Ç÷»ö¼ÒÀÇ »ý¼ºÀÌ ÃæºÐÈ÷ ÇàÇÏ¿©ÁöÁö ¾Ê±â ¶§¹®¿¡ ÀûÇ÷±¸ ¼öº¸´Ùµµ Ç÷»ö¼Ò ³óµµ°¡ ÇöÀúÇÏ°Ô °¨¼ÒÇÑ´Ù. 2. ö ÀúÀå·®ÀÇ ÀúÇÏ, °áÇÌ, Ç÷û ö ³óµµÀÇ ÀúÇÏ, transferrin¾ç »ó½Â, transferrin Æ÷È­µµÀÇ ÀúÇÏ, Àú»ö¼Ò¼º ´ëÀûÇ÷±¸¸¦ Ư¡À¸·Î ÇÏ´Â ºóÇ÷.
  • isolated T-cell deficiency
    T ¼¼Æ÷ °áÇÌ
  • lactase deficiency
    ¶ôŸÁ¦ °áÇÌ
  • mental deficiency
    Áö´É ¹Ú¾à, Áö´É ¹Ú¾àÁõ, Á¤½Å ¹Ú¾àÁõ
    ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇØ¼­ Áö´É ¹ß´ÞÀÌ Æò±Õº¸´Ù ³·°í Á¤½ÅÀû, ½ÅüÀû Àå¾Ö·Î ÀÎÇØ »çȸ »ýȰ¿¡ ´ëÇÑ ÀûÀÀÀÌ °ï¶õÇÑ »óÅÂ. Á¤½Å Áöü¶ó°íµµ ÇÑ´Ù. Çö´ë ÀÇÇп¡¼­´Â ÁøÇ༺ ¸¶ºñ¿¡ ÀÇÇÑ Ä¡¸Å³ª ÀϽÃÀûÀÎ Á¤½Å ±â´ÉÀÇ ÅðÇà°ú ±¸º°ÇÏ¿© Ç×±¸ÀûÀÎ Áöü »óŸ¦ ÀǹÌÇÑ´Ù. ¶ÇÇÑ ÀÏ¹Ý Áö´ÉÀÇ °áÇÔ¸¸ÀÌ ¾Æ´Ï¶ó '»çȸ »ýȰ¿¡¼­ÀÇ ½ÇõÀû Áö´É'À̶ó ºÎ¸¦ ¸¸ÇÑ Ãø¸é¿¡µµ ÁÖ¸ñÇÏ°Ô µÇ¸é¼­ Á¤½Å ¹Ú¾àÀÇ ºÐ·ù´Â »çȸÀÇ ÀûÀÀµµ¿Í »çȸÀû »ýȰ ´É·Â Á¤µµ¸¦ ¹èÇÕ½ÃŰ°Ô µÇ¾ú´Ù.
  • mineral deficiency
    ¹«±âÁú °áÇÌ, ¹«±âÁú °áÇÌÁõ
  • myeloperoxidase deficiency
    ¸¶ÀÌ¿¤·Î ÆÛ·Ï½Ãµ¥À̽º °áÇÌÁõ
    »ó¿°»öü¼º ¿­¼º ÇüÁú·Î À¯ÀüµÇ¸ç, Áß¼º±¸¿Í ´Ü±¸ÀÇ È£¾ÆÁÖ¸£¼º °ú¸³ ³»¿¡ MPO°¡ ÀüÇô ¾ø´Ù.
  • myoadenylate deaminase deficiency
    ¸¶ÀÌ¿À ¾Æµ¥´Ò·¹ÀÌÆ® µð¾Æ¹Ì³×À̽º °áÇÌÁõ
  • nutrition deficiency
    ¿µ¾ç °áÇÌÁõ
  • nutritional deficiency
    ¿µ¾ç °áÇÌ
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pyridoxine deficiency
    ÇǸ®µ¶½Å °áÇÌ
  • salt deficiency
    ¿°·ù °áÇÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
murine acquired immunodeficiency syndrome <syndrome> Acquired defect of cellular immunity that occurs in mice infected with mouse leukaemia viruses (mulv). The syndrome shows striking similarities with human aids and is characterised by lymphadenopathy, profound immunosuppression, enhanced susceptibility to opportunistic infections, and B-cell lymphomas.
(12 Dec 1998)
hospital acquired pneumonia A type of pneumonia that is caused by bacteria contracted during a hospitalisation. These hospital-acquired infections tend to be more difficult to treat due to the bacteria's relative resistance to common forms of antibiotic therapy. Risk of nosocomial (hospital-acquired) infection is a major determinant when a physician decides whether or not the risks outweigh the benefits concerning necessity for hospitalisation.
(27 Sep 1997)
simian acquired immunodeficiency syndrome <syndrome> Acquired defect of cellular immunity that occurs naturally in macaques infected with srv serotypes, experimentally in monkeys inoculated with srv or mason-pfiser monkey virus (mpmv), or in monkeys infected with siv.
(12 Dec 1998)
nose deformities, acquired Deformities of the nose acquired after birth from injury or disease.
(12 Dec 1998)
dyslexia, acquired Loss of previously possessed reading facility, visual aphasia, or word blindness due to a brain lesion.
(12 Dec 1998)
immunity, maternally-acquired Resistance to a disease-causing agent induced by the introduction of maternal immunity into the foetus by transplacental transfer or into the neonate through colostrum and milk.
(12 Dec 1998)
ear deformities, acquired Distortion or disfigurement of the ear caused by disease or injury after birth.
(12 Dec 1998)
joint deformities, acquired Deformities acquired after birth as the result of injury or disease. The joint deformity is often associated with rheumatoid arthritis and leprosy.
(12 Dec 1998)
feline acquired immunodeficiency syndrome <syndrome> Acquired defect of cellular immunity that occurs in cats infected with feline immunodeficiency virus (fiv) and in some cats infected with feline leukaemia virus (felv).
(12 Dec 1998)
foot deformities, acquired Distortion or disfigurement of the foot, or a part of the foot, acquired through disease or injury after birth.
(12 Dec 1998)
abdominal muscle deficiency syndrome <syndrome> Congenital absence (partial or complete) of abdominal muscles, in which the outline of the intestines is visible through the protruding abdominal wall; in males, genitourinary anomalies (urinary tract dilation and cryptorchidism) are also found; genetics unclear.
(05 Mar 2000)
adult lactase deficiency Onset of lactase deficiency, with resulting milk intolerance and malabsorption, in adulthood. Inherited forms may not be manifested until adulthood; any process that damages the intestinal lining cells can cause lactase deficiency in adults.
(05 Mar 2000)
alpha-1 antitrypsin deficiency <chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues.
The lack of this protein leads to damage of various organs, but mainly to the lung and liver.
symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
(12 Dec 1998)
alpha-1-proteinase deficiency Absence of a serum proteinase inhibitor that may cause nodular non-suppurative panniculitis.
(05 Mar 2000)
alpha-antitrypsin deficiency <enzyme> A specific enzyme (alpha 1 antitrypsinase) that when absent genetically can result in panacinar emphysema (lung disease) and liver disease.
There is no specific treatment for this condition other than supportive care for the liver and lung complications.
Medications such as alpha-1proteinase inhibitor is given regularly to these patients.
Incidence: approximately 1 in 10,000.
(02 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á